-

SmithRx Teams up With Mark Cuban Cost Plus Drug Company to Reduce Prescription Drug Costs for America’s Patients and Employers

The leading pass-through PBM will enable members on its plans to access fairly-priced drugs through Mark Cuban Cost Plus Drug Company

SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a next-generation pharmacy benefits management (PBM) company, has integrated Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) into its pharmacy network to expand access to affordable prescriptions for its members.

Pharmacy costs have been rising rapidly over the past decade, putting strain on patients and employers throughout the country. SmithRx was founded in 2016 with the goal of reducing these costs by operating with a 100% transparent, pass-through PBM business model. With this approach, SmithRx is forging new pathways to affordable drugs while giving clients full access to their data. SmithRx’s simple per-claim revenue model contrasts with legacy PBMs’ use of spread pricing and is fully aligned with its clients’ affordability goals.

Cost Plus Drugs is pursuing the mission of prescription drug affordability by building an innovative pharmacy model that delivers medications at cost, plus a straightforward 15% markup, along with a $3 dispensing fee and shipping fee. Like SmithRx, Cost Plus Drugs is reinventing their industry by putting transparency, simplicity, and clarity at the forefront of their business model.

SmithRx members will have access to select medications through Cost Plus Drugs within the next quarter.

“As two companies committed to fixing the drug supply chain by putting our clients and patients first and adhering to our common values of transparency and simplicity, the collaboration between SmithRx and Cost Plus Drugs makes a lot of sense,” said Jake Frenz, CEO and Founder of SmithRx. “We are excited to deliver more drug affordability pathways to our members through this relationship.”

“As a practicing physician I saw first-hand the danger of patients not taking their medications because they couldn't afford them,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “I founded the Mark Cuban Cost Plus Drug Company to help solve this problem and provide a way for patients to receive their medication at an affordable price. We already offer transparent, low prices to cash-pay consumers and are excited to now be working with PBMs like SmithRx to further reduce the cost to patients, and to keep the patient record complete from both a clinical and financial perspective.”

About SmithRx

SmithRx reduces total drug costs and improves health outcomes with 100% pass-through pricing and the world’s most advanced PBM technology. With hundreds of broker and TPA partners, SmithRx has simplified pharmacy benefits with its leading-edge technology and easily-integrated cloud infrastructure, resulting in lower pharmacy costs for employers. Members benefit from SmithRx’s clinical programs and Drug Acquisition Platform to easily manage their prescription benefits and reduce overall drug spend.. With offices in California and Utah, SmithRx was founded with the mission of offering a simple, completely transparent, cloud-based alternative to traditional PBMs. For additional information on SmithRx, visit www.smithrx.com or send an email to marketing@smithrx.com.

About Mark Cuban Cost Plus Drug Company

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 1,000 prescription products, delivered by mail to thousands of happy customers every day. Cost Plus Drugs is working with health plans, managed-care organizations, pharmacy benefits managers (PBMs) and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide.

Contacts

Sam Slaughter
VP Revenue
marketing@smithrx.com

SmithRx


Release Summary
SmithRx teams up with Mark Cuban Cost Plus Drug Company to reduce prescription drug costs for America’s patients and employers.
Release Versions

Contacts

Sam Slaughter
VP Revenue
marketing@smithrx.com

Social Media Profiles
More News From SmithRx

SmithRx Introduces Stelara Biosimilars to Its Autoimmune Program, Helping Clients Save a Projected $14.5M in Prescription Drug Costs

SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Program, including the introduction of Stelara biosimilars to its offering, new low-cost Humira and Stelara biosimilars for pediatric members, and a partnership with Costco Specialty Pharmacy alongside its long-standing relationship with Mark Cuban Cost Plus Drugs. As a major component of the Connect 360 Autoimmune Prog...

SmithRx Unveils 2024 Growth Momentum, Reducing Pharmacy Benefit Costs by an Average of 30%

SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), this week published its newest report, “SmithRx: Milestones and Momentum in 2024,” which unveiled the company’s significant growth, cost savings, customer satisfaction, and market traction from 2024. The momentum SmithRx achieved over the past year is a direct result of the company’s commitment to challenging legacy models, driving innovation, and delivering value beyond dollars and...

SmithRx, Modern Healthcare Best of Business, Reaches New Level of Growth and Customer Impact

SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a transparent and 100% pass-through pharmacy benefits manager (PBM), today shared new growth figures that showcase the company’s significant momentum and landmark achievements from the past year. “Employer plan sponsors are increasingly demanding alternative options to the legacy PBMs,” said Jake Frenz, founder and CEO of SmithRx. “The interest and growth SmithRx and other transparent PBMs are seeing demonstrates the viability of these alternative PBM mo...
Back to Newsroom